Another antiviral drug maker focused on treating Hepatitis C that's experiencing a solid run...
Nov 12 2012, 15:15 ET
Another antiviral drug maker focused on treating Hepatitis C that's experiencing a solid run higher today is Idenix Pharmaceutical (IDIX +11.5%). On Saturday, the company announced positive study results for its clinical-stage hep C drug candidates – IDX719 and IDX184, and presented updated cardiovascular safety and antiviral activity data from phase IIb studies of IDX184. The results were presented at the Annual Meeting for the American Association for the Study of Liver Diseases in Boston.